

## Original Article

# Low riboflavin intake is associated with cardiometabolic risks in Korean women

Woo-young Shin MD<sup>1,2</sup>, Jung-ha Kim MD, PhD<sup>1</sup><sup>1</sup>Department of Family Medicine, Chung-ang University Medical Center, Chung-ang University College of Medicine, Seoul, Republic of Korea<sup>2</sup>Department of Pathology, Chung-ang University College of Medicine, Seoul, Republic of Korea

**Background and Objectives:** Metabolic syndrome is a leading global public health concern. Nutritional approaches are important for preventing and managing cardiometabolic risks, including metabolic syndrome. The aim of this study was to examine the potential association between riboflavin intake and cardiometabolic risks according to sex among Koreans. **Methods and Study Design:** We used data from the Korea National Health and Nutrition Examination Survey 2015–2016, a nationwide cross-sectional survey that assesses the health and nutritional status of the Korean population. A total of 6,062 individuals aged  $\geq 19$  years were included. The nutrition survey was performed using 24-h dietary recall. **Results:** A significant association was observed between low riboflavin intake with only increased HDL-cholesterol (OR 1.362, 95% CI 1.017–1.824,  $p=0.038$ ) among metabolic syndrome and its components in men, whereas insufficient riboflavin intake was positively associated with hypertension (OR 1.352, 95% CI 1.085–1.685,  $p=0.007$ ), diabetes (OR 1.493, 95% CI 1.137–1.959,  $p=0.004$ ) and metabolic syndrome (OR 1.289, 95% CI 1.014–1.640,  $p=0.038$ ) in women after adjusting for the other covariates. For post-menopausal women, central obesity was also correlated with insufficient riboflavin intake (OR 1.315, 95% CI 1.019–1.696,  $p=0.035$ ). **Conclusions:** Insufficient riboflavin intake may contribute to development of cardiometabolic disorder, particularly in women. It was also found that riboflavin may have different influences on its risks in women according to menopausal status. This study highlighted the importance of public policies targeted at these sex-specific groups for reducing cardiometabolic risks.

**Key Words:** riboflavin, vitamin B-2, metabolic syndrome, cardiometabolic risk, women

## INTRODUCTION

Cardiometabolic disorders, such as CVD and type 2 diabetes, are currently the leading causes of mortality and public health concerns worldwide.<sup>1</sup> Metabolic syndrome (MetS) is a cluster of conditions, including central obesity, high blood sugar, high blood pressure (BP), high serum triglycerides (TGs) and low serum HDL-cholesterol, and refers to a core of cardiometabolic risks.<sup>2,3</sup> It was estimated that one in three adults had MetS in the United States.<sup>4</sup> Similarly, the prevalence of MetS reached 22.4% among Korean adults in 2015.<sup>5</sup> Although its cause remains unclear, MetS may be attributable to an underlying disorder of energy storage and utilisation, followed by oxidative injury. To this end, nutritional approaches are important for preventing or managing the syndrome.

Riboflavin, also known as vitamin B-2, is a water-soluble vitamin found in a variety of foods including dairy products, meat, fish, and green vegetables.<sup>6</sup> It is essential for haematological, neurological, cardiovascular, and endocrine system functioning by aiding normal tissue respiration via redox reactions and energy metabolism, with flavin adenine dinucleotide (FAD) and flavin mononucleotide (FMN) as biologically active forms.<sup>6</sup> A recent national nutrition survey in Korea reported poor average riboflavin intake below the Estimated Average Requirement (EAR) for approximately half of Korean people

(41.7% in 2016).<sup>7</sup>

Despite the importance and insufficient intake of riboflavin, studies regarding how riboflavin might reduce cardiometabolic risk are limited. Further, to the best of our knowledge, there has been no study on sex-based differences in the association of riboflavin intake with MetS that used a large, nationwide sample. Therefore, the aim of this study was to examine the association between riboflavin intake and cardiometabolic risks (such as MetS) according to sex-based differences among Korean adults from 2015 to 2016.

## METHODS

### Data source and study population

The Korea National Health and Nutrition Examination Survey (KNHANES) is a nationwide cross-sectional survey that assesses the health and nutritional status of a representative Korean population. The survey was per-

**Corresponding Author:** Dr Jung-ha Kim, Department of Family Medicine, Chung-ang University Medical Center, 102, Heukseok-ro, Dongjak-gu, Seoul 06973, Republic of Korea.

Tel: 82-2-6299-1889; Fax: 82-2-6299-2064

Email: girlpower219@cau.ac.kr

Manuscript received 18 December 2018. Initial review completed 01 January 2019. Revision accepted 21 March 2019.

doi:

formed by the Korea Centers for Disease Control and Prevention.<sup>8</sup> This study was based on data obtained from KNHANES 2015–2016. Participants were adults, aged 19 years or older, who participated in at least one health interview, physical examination, laboratory measure, or nutrition survey. Participants who were aged 18 years or younger, pregnant or lactating were excluded due to potential unexpected metabolic effects and nutritional requirements or other covariates. Current smokers were also excluded considering the obvious sex-specific differences in the rate of current smoking among Korean adults (40.7% for men and 6.4% for women in 2016) and the strong evidence as an important risk factor for CVD.<sup>7,9</sup> For the KNHANES, informed consent was obtained from all participants. The institutional review board of the Korea Centers for Disease Control and Prevention approved the KNHANES (2015-01-02-6C).

#### **Demographic and health-related covariates**

Information on participants' demographics, including age, sex, health-related behaviours (e.g. cigarette smoking, alcohol use and physical activity), menopausal status, use of oral contraceptives and diagnosed medical conditions, was gathered through face-to-face interviews or self-report. Participants who smoked  $\geq 100$  cigarettes in their lifetime and who reported smoking currently were regarded as 'current' smokers. Participants were considered alcohol 'users' if they consumed seven or more drinks for men, and five or more drinks for women, at least twice a week. The 'regular' physical activity group consisted of those who engaged in moderate activities for  $\geq 30$  min in a day, at least 5 d a week, or in vigorous activities for  $\geq 20$  min in a day, at least 3 d a week.<sup>10</sup> Participants were also asked if they had chronic health conditions, including hypertension, diabetes, or dyslipidaemia that had been diagnosed by a health professional. The information on chronic conditions was also based on self-reported medical history.

#### **Clinical and laboratory measurements**

The health examination collected information regarding anthropometry, BP and blood analysis. According to standardised protocols, all health examinations were conducted by trained medical personnel and all pieces of equipment were calibrated regularly. BMI was calculated by dividing weight in kilograms by the square of height in metres, using data obtained wearing minimal clothing. Waist circumference (WC) was measured at the midpoint of the interval between the lower part of rib and the upper part of the iliac crest. BP was measured on each participant's right arm while seated and after a 5 min rest using a standard sphygmomanometer [Wall Unit 33(0850), Baumanometer®, NY, US]. Venous blood samples were obtained for measurement of blood glucose and lipid profile after fasting for 12 h.

#### **Nutrition assessment**

A nutrition survey was conducted using a 24-h dietary recall by professional interviewers consisted of nurses, a dietitian, and health science graduates. Daily intake of energy and nutrients was further calculated from consumed foods or dietary supplements that were reported.

#### **Definition of MetS**

MetS was defined according to the US National Cholesterol Education Programme's Adult Treatment Panel III (NCEP/ATP III) criteria, adapted for Asians.<sup>11</sup> MetS was diagnosed as the presence of at least three of the following five criteria: (1) central obesity (WC  $\geq 90$  cm for men or  $\geq 85$  cm for women); (2) HDL-cholesterol  $< 40$  mg/dL for men,  $< 50$  mg/dL for women; (3) serum TGs  $\geq 150$  mg/dL; (4) increased BP (systolic  $\geq 130$  mmHg, diastolic  $\geq 85$  mmHg, or under treatment of hypertension); (5) fasting blood glucose (FBG)  $\geq 100$  mg/dL or under treatment for diabetes.

#### **Statistical analysis**

Statistical analyses were conducted using the SPSS, version 23 (SPSS Inc., Chicago, IL, USA). All analyses used sample weights assigned to participants to represent the Korean population, which were considered using estimated response probability and post-stratification. The participants were categorised into two groups according to riboflavin intake or the presence of MetS, to identify and compare between-group characteristics of the participants. Riboflavin intake was classified by adherence to the Recommended Nutrient Intake (RNI): 1.5 mg/d for men and 1.2 mg/d for women, according to DRIs for Koreans (KDRI).<sup>12</sup> Categorical variables were expressed as frequencies and weighted percentages of participants using Rao-Scott adjusted chi-squared tests, while continuous variables were expressed as means with their standard errors using ANOVA. Multivariate binary logistic regression was used to estimate the association between riboflavin intake and MetS, adjusting for age, alcohol use, physical activity, oral contraceptive use, menopause, and each riboflavin intake from the 4 most used food sources including cereals, vegetables, meats, and eggs, and supplementary sources. Use of oral contraceptives was subjected to multivariate modelling to control for residual confounding, considering the interaction between oral contraceptives and riboflavin, as suggested by Newman et al.<sup>13</sup> Adjusted ORs and 95 % CI for MetS and other cardiometabolic risks were calculated according to adherence to the RNI of riboflavin. *p* values of  $< 0.05$  were considered statistically significant.

## **RESULTS**

A total of 20,311 (9,505 in 2015 and 10,806 in 2016) Korean men and women were selected using a two-stage stratified cluster and complex sampling method in the KNHANES 2015–2016. Of these, 15,530 (7,380 in 2015 and 8,150 in 2016) participants who participated in one or more health interviews, health examinations, or nutrition surveys were included. Finally, a total of 6,062 (2,023 for men and 4,039 for women) individuals were included in the statistical analysis after participants who were aged  $< 19$  years old, pregnant, lactating, current smoking or who had missing data were excluded.

#### **Characteristics of participants according to riboflavin intake**

The mean intake of riboflavin at baseline was  $1.61 \pm 0.03$  mg/d in men and  $1.21 \pm 0.01$  mg/d in women (Table 1). Overall, 58.8% (53% men and 57.2% women) of the par-

**Table 1.** General characteristics of men and women, according to riboflavin intakes

Variables <sup>†</sup>	Men		Total	<i>p</i> value <sup>‡</sup>	Women		Total	<i>p</i> value
	Riboflavin intake (mg/day)				Riboflavin intake (mg/day)			
	<1.5	≥1.5			<1.2	≥1.2		
Total	1174 (53.0)	849 (47.0)	2023 (100.0)		2388 (57.2)	1651 (42.8)	4039 (100.0)	
Age (years)				<0.001				<0.001
19-29	121 (19.5)	105 (18.6)	226 (19.1)		209 (14.3)	184 (17.5)	393 (15.7)	
30-39	84 (11.4)	122 (19.9)	206 (15.4)		320 (14.5)	291 (18.5)	611 (16.2)	
40-49	131 (16.4)	158 (21.6)	289 (18.8)		386 (18.6)	374 (23.2)	760 (20.6)	
50-59	168 (17.8)	169 (21.6)	337 (19.5)		436 (19.8)	384 (22.4)	820 (21.0)	
60-69	291 (15.4)	180 (11.3)	471 (13.5)		481 (15.1)	273 (12.4)	754 (13.9)	
≥70	379 (19.5)	115 (7.1)	494 (13.7)		556 (17.7)	145 (5.9)	701 (12.7)	
Alcohol use				0.322				0.016
Yes	118 (11.3)	119 (12.9)	237 (12.1)		65 (2.8)	65 (4.5)	130 (3.5)	
No	1056 (88.7)	730 (87.1)	1786 (87.9)		2323 (97.2)	1586 (95.5)	3909 (96.5)	
Regular physical activity				<0.001				<0.001
Yes	533 (52.4)	509 (63.5)	1042 (57.6)		975 (45.0)	786 (51.2)	1761 (47.7)	
No	641 (47.6)	340 (36.5)	981 (42.4)		1413 (55.0)	865 (48.8)	2278 (52.3)	
Oral contraceptive use								0.013
Yes	0 (0.0)	0 (0.0)	0 (0.0)		492 (18.8)	272 (15.4)	764 (17.4)	
No	1174 (100.0)	849 (100.0)	2023 (100.0)		1896 (81.2)	1379 (84.6)	3275 (82.6)	
Menopause								<0.001
Yes	0 (0.0)	0 (0.0)	0 (0.0)		1429 (50.6)	765 (38.7)	2194 (45.5)	
No	1174 (100.0)	849 (100.0)	2023 (100.0)		959 (49.4)	886 (61.3)	1845 (54.5)	
Hypertension				0.002				<0.001
Yes	507 (34.8)	299 (27.5)	806 (31.4)		876 (29.9)	360 (17.7)	1236 (24.7)	
No	667 (65.2)	550 (72.5)	1217 (68.6)		1512 (70.1)	1291 (82.3)	2803 (75.3)	
Diabetic mellitus				<0.001				<0.001
Yes	213 (13.4)	99 (7.9)	312 (10.8)		327 (11.6)	120 (5.8)	447 (9.1)	
No	961 (86.6)	750 (92.1)	1711 (89.2)		2061 (88.4)	1531 (94.2)	3592 (90.9)	
Dyslipidemia				0.319				<0.001
Yes	408 (33.9)	285 (31.4)	693 (32.7)		827 (31.4)	472 (25.0)	1299 (28.7)	
No	766 (66.1)	564 (68.6)	1330 (67.3)		1561 (68.6)	1179 (75.0)	2740 (71.3)	
Metabolic syndrome				0.169				<0.001
Yes	394 (30.0)	260 (26.8)	654 (28.5)		764 (27.4)	359 (18.2)	1123 (23.5)	
No	780 (70.0)	589 (73.2)	1369 (71.5)		1624 (72.6)	1292 (81.8)	2916 (76.5)	
Central obesity				0.048				<0.001
Yes	359 (29.2)	300 (33.9)	659 (31.4)		797 (29.6)	424 (22.6)	1221 (26.6)	
No	815 (70.8)	549 (66.1)	1364 (68.6)		1591 (70.4)	1227 (77.4)	2818 (73.4)	
Blood pressure (mmHg): systolic ≥130 or diastolic ≥85 or medication for hypertension				0.002				<0.001
Yes	646 (47.8)	397 (40.1)	1043 (44.2)		1048 (36.6)	489 (25.0)	1537 (31.6)	
No	528 (52.2)	452 (59.9)	980 (55.8)		1340 (63.4)	1162 (75.0)	2502 (68.4)	

HDL: high-density lipoprotein; BMI: Body Mass Index; LDL: low-density lipoprotein; SFA: saturated fatty acids; MUFA: monounsaturated fatty acids; PUFA: polyunsaturated fatty acids

<sup>†</sup>Categorical variable: unweighted n (weighted %), continuous variable: mean±standard error.

<sup>‡</sup>*p* values are from Rao-scott  $\chi^2$  test or ANOVA


**Table 1.** General characteristics of men and women, according to riboflavin intakes (cont.)

Variables <sup>†</sup>	Men		Total	<i>p</i> value <sup>‡</sup>	Women		Total	<i>p</i> value
	Riboflavin intake(mg/day)				Riboflavin intake(mg/day)			
	<1.5	≥1.5			<1.2	≥1.2		
Fasting blood glucose (mg/dL): ≥100 or medication for diabetes				0.284				<0.001
Yes	543 (38.4)	359 (35.7)	902 (37.1)		812 (30.7)	420 (22.0)	1232 (27.0)	
No	631 (61.6)	490 (64.3)	1121 (62.9)		1576 (69.3)	1231 (78.0)	2807 (73.0)	
Triglycerides(mg/dL) ≥150				0.352				0.007
Yes	403 (35.0)	283 (32.6)	686 (33.9)		582 (21.6)	326 (17.8)	908 (20.0)	
No	771 (65.0)	566 (67.4)	1337 (66.1)		1806 (78.4)	1325 (82.2)	3131 (80.0)	
HDL-cholesterol (mg/dL): men <40, women <50				0.004				0.003
Yes	331 (26.5)	185 (19.7)	516 (23.3)		1029 (39.5)	628 (34.4)	1657 (37.3)	
No	843 (73.5)	664 (80.3)	1507 (76.7)		1359 (60.5)	1023 (65.6)	2382 (62.7)	
BMI (kg/m <sup>2</sup> )	24.4±0.13	24.9±0.14	24.6±0.10	0.003	23.5±0.10	23.2±0.10	23.4±0.07	0.019
Waist circumference (cm)	86.1±0.34	86.7±0.35	86.4±0.25	0.160	79.7±0.29	78.2±0.29	79.1±0.23	<0.001
Systolic blood pressure (mmHg)	121±0.49	119±0.55	120±0.38	0.005	117±0.43	113±0.41	115±0.33	<0.001
Diastolic blood pressure (mmHg)	77.2±0.34	78.3±0.36	77.7±0.26	0.023	73.3±0.24	73.0±0.28	73.1±0.19	0.402
Fasting blood glucose (mg/dL)	103±0.99	99.7±0.80	101.2±0.69	0.015	98.4±0.55	95.4±0.51	97.1±0.41	<0.001
Total cholesterol (mg/dL)	189±1.36	191±1.56	190±1.05	0.187	192±0.87	194±1.08	193±0.69	0.180
Triglycerides (mg/dL)	148±4.27	147±5.71	148±3.55	0.967	115±1.75	108±2.13	112±1.46	0.005
LDL-cholesterol (mg/dL)	113±1.23	114±1.33	113±0.94	0.320	115±0.76	116±0.95	116±0.62	0.346
HDL-cholesterol (mg/dL)	47.4±0.41	48.5±0.43	47.9±0.28	0.078	54.1±0.32	56.1±0.39	55.0±0.26	<0.001
Total energy intake (kcal/day)	1875±21.6	2989±43.2	2399±29.2	<0.001	1387±12.43	2158±20.4	1717±13.6	<0.001
Carbohydrates intake (g/day)	301±3.43	406±5.62	350±3.73	<0.001	236±2.42	323±3.42	273±2.30	<0.001
Protein intake (g/day)	60.1±0.83	117±3.10	87.0±1.74	<0.001	44.1±0.47	81.4±0.97	60.1±0.64	<0.001
Fat intake (g/day)	35.6±0.90	79.1±2.21	56.0±1.39	<0.001	26.6±0.49	55.2±0.94	38.8±0.57	<0.001
SFA intake (g/day)	10.0±0.28	23.0±0.70	16.1±0.42	<0.001	7.51±0.16	15.7±0.30	11.0±0.17	<0.001
MUFA intake (g/day)	11.3±0.36	25.8±0.80	18.1±0.50	<0.001	8.14±0.17	17.7±0.33	12.2±0.20	<0.001
PUFA intake (g/day)	9.08±0.25	19.4±0.70	13.9±0.40	<0.001	6.82±0.13	13.7±0.30	9.74±0.17	<0.001
Dietary fiber intake (g/day)	21.5±0.38	32.7±0.59	26.8±0.40	<0.001	17.4±0.22	28.1±0.45	22.0±0.26	<0.001
Total riboflavin intake (mg/day)	0.98±0.01	2.33±0.04	1.61±0.03	<0.001	0.75±0.01	1.81±0.02	1.21±0.01	<0.001
Riboflavin intake from cereals and grains	0.18±0.01	0.37±0.02	0.27±0.01	<0.001	0.14±0.00	0.26±0.01	0.18±0.00	<0.001
Riboflavin intake from meats	0.12±0.01	0.36±0.02	0.23±0.01	<0.001	0.08±0.00	0.23±0.01	0.15±0.00	<0.001
Riboflavin intake from vegetables	0.18±0.00	0.32±0.01	0.24±0.01	<0.001	0.13±0.00	0.27±0.01	0.19±0.00	<0.001
Riboflavin intake from eggs	0.11±0.01	0.35±0.02	0.21±0.01	<0.001	0.08±0.00	0.35±0.01	0.20±0.01	<0.001
Riboflavin intake from fruits	0.04±0.00	0.07±0.00	0.06±0.00	<0.001	0.05±0.00	0.08±0.00	0.06±0.00	<0.001
Riboflavin intake from milks and dairy products	0.06±0.00	0.18±0.01	0.11±0.01	<0.001	0.06±0.00	0.16±0.01	0.10±0.00	<0.001
Riboflavin intake from supplements	0.29±0.00	0.70±0.05	0.48±0.02	0.222	0.21±0.00	0.46±0.02	0.32±0.00	0.313

HDL: high-density lipoprotein; BMI: Body Mass Index; LDL: low-density lipoprotein; SFA: saturated fatty acids; MUFA: monounsaturated fatty acids; PUFA: polyunsaturated fatty acids

<sup>†</sup>Categorical variable: unweighted n (weighted %), continuous variable: mean±standard error.

<sup>‡</sup>*p* values are from Rao-scott  $\chi^2$  test or ANOVA.



**Figure 1.** A schematic diagram that presents the pathways from insufficient riboflavin intake with food or supplementary sources to the development of cardiometabolic risks, including metabolic syndrome, via impaired modulation of energy metabolism along with other personal behaviours such as physical activity as energy expenditure.

ticipants had daily riboflavin intake below the RNI for Koreans. Sociodemographic and cardiometabolic characteristics, relative to riboflavin intake at baseline, are shown in Table 1. There were significant between-group differences in mean riboflavin intake when we compared intakes that were below and above the RNI for riboflavin, in both sexes ( $0.98 \pm 0.01$  vs  $2.33 \pm 0.04$  mg/d,  $p < 0.001$  for men and  $0.75 \pm 0.01$  vs  $1.81 \pm 0.02$  mg/d,  $p < 0.001$  for women).

#### **Characteristics of participants with and without MetS**

Among the 6,062 participants at baseline, there were 654 (28.5%) men and 1,123 (23.5%) women with MetS and

their general characteristics are listed in Supplementary Tables 1 and 2. Among men, those aged 50-59 years had the highest prevalence of MetS, whereas the prevalence of MetS increased with age in women ( $p < 0.001$ ). Unlike non-MetS women, women with MetS were more likely to be post-menopausal (76.8% vs 23.2%,  $p < 0.001$ ). The rate of participants with MetS was higher among post-menopausal women than pre-menopausal women (39.6% vs 10%,  $p < 0.001$ ). As shown in Supplementary Table 2, while half of post-menopausal women had hypertension, the prevalence of hypertension in pre-menopausal women was only 6.7% in the present study. Mean daily riboflavin intake was significantly lower in the MetS than in the

non-MetS group for both men ( $1.53 \pm 0.05$  vs  $1.65 \pm 0.04$ ,  $p=0.038$ ) and women ( $1.05 \pm 0.02$  vs  $1.25 \pm 0.02$ ,  $p<0.001$ ).

#### ***Association of riboflavin intake with MetS and related conditions in men and women***

Table 2 presents the estimated OR and 95 % CI of MetS and related chronic conditions, by daily riboflavin intake, in men and women. Here, we used binary logistic regression analysis, adjusting for other covariates. ORs were estimated by comparing the prevalence of each chronic condition, by daily riboflavin intake, using the RNI for riboflavin as a reference. In men, we found no significant relationship between poor riboflavin intake and the prevalence of MetS or other related chronic conditions, except low HDL-cholesterol (OR 1.362, 95% CI 1.017-1.824,  $p=0.038$ ), after adjusting for covariates (Table 2). On the other hand, there was significant inverse association between riboflavin intake and hypertension (OR 1.352, 95% CI 1.085-1.685,  $p=0.007$ ) and between riboflavin intake and diabetes (OR 1.493, 95% CI 1.137-1.959,  $p=0.004$ ) after adjusting for covariates in women. We also found that insufficient riboflavin intake was significantly correlated with the prevalence of MetS (OR 1.289, 95% CI 1.014-1.640,  $p=0.038$ ) after adjusting for covariates in women.

#### ***Association of riboflavin intake with MetS and related chronic conditions in pre- and post-menopausal women***

There were significantly more post-menopausal women in the MetS group than in the non-MetS group (Supplementary Table 1). We therefore evaluated the association of riboflavin intake and individual components of MetS, according to menopausal status, in women (Table 3). Table 3 further shows the ORs of individual components of MetS and related chronic diseases, by riboflavin intake, in pre- and post-menopausal women. There was no significant relationship between riboflavin intake and BP in premenopausal women ( $p>0.05$ ), whereas insufficient riboflavin intake was positively associated with hypertension (OR 1.479, 95% CI 1.158-1.889,  $p=0.002$ ) in postmenopausal women after adjusting for covariates. Riboflavin intake was inversely associated with diabetes in both pre- (OR 1.664, 95% CI 1.070-2.589,  $p=0.024$ ) and postmenopausal women (OR 1.426, 95% CI 1.052-1.932,  $p=0.022$ ). We found no significant association between riboflavin intake and central obesity in premenopausal women ( $p=0.956$ ). However, among postmenopausal women with insufficient riboflavin intake, there was a positive correlation with central obesity after adjusting for other covariates (OR 1.315, 95% CI 1.019-1.696,  $p=0.035$ ). There was also a significant association of poor riboflavin intake with the prevalence of MetS only in postmenopausal women (OR 1.304, 95% CI 1.005-1.692,  $p=0.045$ ).

## **DISCUSSION**

Among Korean adults, insufficient riboflavin intake appears common, with 58.8% of participants exhibiting daily riboflavin intake below the RNI. This result is similar to the findings from a previous national nutrition survey in Korea that reported poor riboflavin intake (below EAR) among half of Koreans.<sup>7</sup> The prevalence of MetS

was 28.5% in men and 23.5% in women. Among men, those aged 50-59 years had the highest prevalence of MetS, whereas in women, the prevalence of MetS increased with age. There were significantly more postmenopausal women in the MetS group than in the non-MetS group. Our findings are consistent with those of a previous report regarding the differences in prevalence of MetS by sex and age.<sup>5</sup> In men, no significant relationship between poor riboflavin intake and the prevalence of MetS or any other related chronic condition was found, except low HDL-cholesterol, after adjusting for covariates. On the other hand, there was a significant and positive association of insufficient riboflavin intake with the prevalence of hypertension, diabetes and also MetS after adjusting for covariates in women. This finding suggests that riboflavin deficiency contributes to the development of cardiometabolic risks, particularly in women. Additionally, riboflavin intake may exert disproportional effects on postmenopausal women compared with their premenopausal counterparts (Figure 1).

Evidenced managements of MetS include improving a wide range of personal behaviours, such as maintaining a healthy body weight, engaging in regular physical activity and consuming a healthy diet. Although, there has been no agreed pathophysiology for MetS or other cardiometabolic disorders, the effect of obesity, considering only BMI, on CVD is varied and affected by other cardiometabolic status.<sup>14</sup> Wahlqvist et al suggested a unified explanatory core mechanism of this syndrome, impaired energy regulation, which was found similarly in different ethnic groups.<sup>15</sup> They proposed disordered energy metabolism with its energy intake and expenditure as a consistent basis of MetS. Furthermore, Kiran et al have found that obesity-related inflammation released pro-inflammatory cytokines from adipose tissue, potentially contributing to the development of numerous cardiometabolic disorders.<sup>16</sup> Riboflavin reportedly plays a role in the regulation of cellular fuel metabolism and mitochondrial energy function,<sup>6</sup> but inflammation-related biomarkers were not analyzed in the present study. Particularly, we also found a significant relationship between poor riboflavin intake and central obesity among postmenopausal women. On the other hand, nutritional studies have found that high intake of foods rich in antioxidants, such as fruit and vegetables, whole grains, and MUFAs and PUFAs, was inversely associated with the development of MetS.<sup>17,18</sup> Antioxidants, including some specific micronutrients, have received worldwide attention since oxidative stress has an important role in the pathogenesis of obesity-related metabolic disorders.<sup>19,20</sup> Avignon et al and Wayne et al have shown that higher dietary or supplementary intake of antioxidants (such as vitamins A, C and E, folic acid, niacin, selenium and zinc) was associated with a reduced cardiometabolic risk.<sup>20,21</sup> Other studies produced mixed results regarding the ties between antioxidant intake and cardiometabolic risk.<sup>19,22</sup> Previous studies conducted in animal models indicated that riboflavin exert a direct or indirect protective effect against oxidative stress by converting or metabolising other antioxidants, including other vitamins and glutathione.<sup>23,24</sup> Similarly, this study showed that sufficient riboflavin intake might help reduce cardiometabolic risks by managing inflam-

**Table 2.** ORs (95% CI) of variables according to riboflavin intake after adjusting for covariates in men and women

Variables	Model	Men			Women		
		Riboflavin intake (mg/day)			Riboflavin intake (mg/day)		
		≥1.5	<1.5	<i>p</i> value	≥1.2	<1.2	<i>p</i> value
		OR	OR (95% CI)		OR	OR (95% CI)	<i>p</i> value
Hypertension	1 <sup>†</sup>	1	1.09 (0.85-1.41)	0.506	1	1.39 (1.15-1.68)	<0.001
	2 <sup>‡</sup>	1	1.06 (0.80-1.40)	0.682	1	1.35 (1.09-1.69)	0.007
Diabetic mellitus	1	1	1.44 (1.01-2.06)	0.045	1	1.53 (1.18-1.97)	0.001
	2	1	1.35 (0.94-1.93)	0.104	1	1.49 (1.14-1.96)	0.004
Dyslipidemia	1	1	1.17 (0.92-1.48)	0.200	1	1.14 (0.97-1.34)	0.111
	2	1	1.26 (0.98-1.63)	0.078	1	1.12 (0.94-1.34)	0.213
Central obesity	1	1	0.78 (0.62-0.98)	0.032	1	1.15 (0.97-1.37)	0.108
	2	1	0.80 (0.62-1.04)	0.092	1	1.12 (0.93-1.36)	0.224
Blood pressure (mmHg): systolic ≥130 or diastolic ≥85 or medication for hypertension	1	1	1.12 (0.89-1.41)	0.338	1	1.22 (1.02-1.46)	0.027
	2	1	1.08 (0.82-1.40)	0.592	1	1.24 (1.02-1.50)	0.030
Fasting blood glucose (mg/dL): ≥100 or medication for diabetes	1	1	0.97 (0.77-1.22)	0.793	1	1.28 (1.08-1.53)	0.006
	2	1	0.95 (0.73-1.24)	0.692	1	1.27 (1.05-1.53)	0.014
Triglycerides (mg/dL) ≥150	1	1	1.18 (0.94-1.47)	0.152	1	1.11 (0.93-1.34)	0.255
	2	1	1.23 (0.96-1.57)	0.102	1	1.05 (0.86-1.28)	0.640
HDL-cholesterol (mg/dL): men <40, women <50	1	1	1.39 (1.06-1.81)	0.016	1	1.11 (0.95-1.29)	0.188
	2	1	1.36 (1.02-1.82)	0.038	1	1.08 (0.92-1.27)	0.363
Metabolic syndrome	1	1	1.06 (0.83-1.36)	0.620	1	1.28 (1.06-1.55)	0.011
	2	1	1.12 (0.86-1.46)	0.410	1	1.29 (1.01-1.64)	0.038

HDL: high-density lipoprotein

<sup>†</sup>Model 1: adjusted for age.<sup>‡</sup>Model 2: adjusted for age, alcohol use, physical activity, oral contraceptives use, menopause, and each riboflavin intake from the 4 most used food sources including cereals, vegetables, meats, and eggs, and supplementary sources.

**Table 3.** ORs (95% CI) of variables according to riboflavin intake after adjusting for covariates in pre- and post-menopausal women

Variables	Model	Pre-menopausal women			Post-menopausal women		
		Riboflavin intake (mg/day)			Riboflavin intake (mg/day)		
		≥1.2	<1.2	<i>p</i> value	≥1.2	<1.2	<i>p</i> value
Hypertension	1 <sup>†</sup>	1	1.00 (0.66-1.50)	0.986	1	1.57 (1.28-1.94)	<0.001
	2 <sup>‡</sup>	1	1.07 (0.68-1.70)	0.768	1	1.48 (1.16-1.89)	0.002
Diabetic mellitus	1	1	1.94 (1.20-3.16)	0.007	1	1.43 (1.08-1.89)	0.013
	2	1	1.66 (1.07-2.59)	0.024	1	1.43 (1.05-1.93)	0.022
Dyslipidemia	1	1	1.16 (0.86-1.58)	0.335	1	1.13 (0.92-1.39)	0.234
	2	1	1.23 (0.88-1.73)	0.231	1	1.09 (0.87-1.37)	0.455
Central obesity	1	1	0.95 (0.73-1.22)	0.670	1	1.37 (1.09-1.70)	0.006
	2	1	1.01 (0.77-1.31)	0.956	1	1.32 (1.02-1.70)	0.035
Blood pressure (mmHg): systolic ≥130 or diastolic ≥85 or medication for hypertension	1	1	0.93 (0.68-1.28)	0.659	1	1.44 (1.17-1.77)	< 0.001
	2	1	1.01 (0.72-1.41)	0.974	1	1.40 (1.10-1.77)	0.006
Fasting blood glucose (mg/dL): ≥100 or medication for diabetes	1	1	1.36 (1.03-1.79)	0.030	1	1.24 (0.98-1.56)	0.070
	2	1	1.38 (1.03-1.85)	0.029	1	1.18 (0.92-1.51)	0.206
Triglycerides (mg/dL) ≥150	1	1	1.11 (0.82-1.51)	0.484	1	1.11 (0.87-1.42)	0.414
	2	1	1.23 (0.89-1.72)	0.215	1	0.94 (0.73-1.23)	0.662
HDL-cholesterol (mg/dL) <50	1	1	1.15 (0.92-1.44)	0.212	1	1.06 (0.85-1.32)	0.603
	2	1	1.15 (0.91-1.45)	0.251	1	0.97 (0.76-1.22)	0.773
Metabolic syndrome	1	1	1.10 (0.79-1.53)	0.588	1	1.40 (1.11-1.76)	0.004
	2	1	1.15 (0.80-1.67)	0.449	1	1.30 (1.01-1.69)	0.045

HDL: high-density lipoprotein

<sup>†</sup>Model 1: adjusted for age.<sup>‡</sup>Model 2: adjusted for age, alcohol use, physical activity, oral contraceptives use, menopause, and each riboflavin intake from the 4 most used food sources including cereals, vegetables, meats, and eggs, and supplementary sources.



mation caused by oxidative stress.<sup>16</sup>

There was a significant and positive relationship between insufficient riboflavin intake and hypertension in women, particularly in post-menopausal women. Like our study, riboflavin intake was inversely associated with BP in participants aged 40-59 years.<sup>25</sup> In another study, McNulty et al. have suggested that riboflavin helped modulate BP by lowering concentrations of homocysteine, particularly in individuals with a specific genotype.<sup>26</sup> Riboflavin modulates concentrations of plasma homocysteine,<sup>27</sup> a risk factor for CVD.<sup>28</sup>

Meanwhile, Mazidi et al have suggested that higher intake of specific nutrients, including riboflavin, all together was associated with lower prevalence of MetS and central obesity, with adverse effects on TGs and HDL-cholesterol concentrations,<sup>29</sup> but a single linked nutrient could not be identified. Our study showed that sufficient intake of riboflavin, as a single nutrient, might help lower the prevalence of MetS and other cardiometabolic risks, and our findings underscore the potential therapeutic and protective effects of riboflavin intake against the development of MetS, especially in women. We also found that poor riboflavin intake contributed partially to low HDL-cholesterol for men. Furthermore, the findings of associations between riboflavin intake and central obesity are remarkable, given the evidence that WC in post-menopausal women had higher risk for CVD-related mortality than other components of MetS.<sup>30</sup>

We believe that our findings of the sex-based effects on cardiometabolic risks are important in regard to public health concerns. The findings of our study have been supported by Chang et al. who showed that increased medical costs in men with MetS were more evident than women among Taiwanese elders.<sup>31</sup> Possible mechanisms surrounding the sex-specific effects of riboflavin on MetS include differences in regional distribution of body fat, including visceral and subcutaneous fat and composition of sex hormones, including oestrogen.<sup>32</sup> Cartier et al. have suggested a similar mechanism that inflammatory markers are influenced by intra-abdominal adiposity in men and mainly by subcutaneous adiposity in women.<sup>32</sup> Moreover, changes in body fat composition, including increased accumulation of abdominal adipose tissue and age-related decreased sex hormone concentrations, may help explain the age- or menopause-related effects of riboflavin on the prevalence of MetS in this study.

We considered the RNI for riboflavin in adults as 1.5 mg for men and 1.2 mg for women. These concentrations are 120% of the EAR, determined by applying a 10% coefficient of variation, based on the KDRI.<sup>12</sup> Here, the EAR is the daily nutrient intake concentrations necessary to meet the requirements of half of the apparently healthy individuals in a target group. The EAR of riboflavin was established after considering that its intake helps maintain normal erythrocyte glutathione reductase activity and urinary excretion of riboflavin without causing clinical deficiencies.

The use of dietary supplements for achieving recommended intakes has recently been widespread, with approximately half of the Korea adults consuming dietary supplements. In 2016, 41.4% of men and 51.0% of women reportedly consumed dietary supplements containing

micronutrients regularly in the past 1 year.<sup>7</sup> Therefore, the present study estimated total riboflavin intake from both foods and supplementary sources. The study by Choi et al showed that urinary riboflavin excretion was positively correlated with total riboflavin intake, rather than only food intake.<sup>33</sup> Urinary riboflavin concentrations reflect tissue saturation under optimal riboflavin status, given that the excess riboflavin supplied into human body is not stored and it is likely to be removed quickly by renal secretion.<sup>6</sup> Therefore, total riboflavin intake might be a means of estimating urinary excretion of riboflavin, potentially reflecting riboflavin status.<sup>34,35</sup> As indicated previously, riboflavin is present in various food sources. Milk and dairy products are the main sources of its intake in Western countries.<sup>36</sup> Recent nationwide nutrition surveys in Korea have reported that meat and meat products, followed by cereals and grains, make the greatest contribution to riboflavin intake in men, whereas the principal sources are eggs and vegetables in women.<sup>7</sup> These differences in dietary habits could reportedly be one possible reason for the sex-based discrepancies in the associations of insufficient riboflavin intake with cardiometabolic risks in the present study. Cardiometabolic risks are reportedly associated with excessive energy intake. Most of the energy consumed by the Korean population is derived from grains and meat.<sup>7</sup> Indeed, the habitual consumptions of meat and grains, as main sources of riboflavin, were reported higher for men than women. Another possibility is that a higher frequency of eating out, probably with energy-rich foods, was more evident in Korea men than in women; 44.3% for men and 23.2% for women in 2016.<sup>7</sup> Therefore, it seems that the association of insufficient riboflavin intake and cardiometabolic risks is influenced in certain circumstances depending on food habitual cultures or personal behaviours; further studies evaluating these possibilities are required.

This study has several limitations. We cannot conclude a temporal relationship between daily riboflavin intake and cardiometabolic risks as our study included a cross-sectional design. Thus, we cannot determine if riboflavin intake concentrations preceded the development of MetS or its individual components. Since some data in our study were based on self-reports, there could be a response bias. Specifically, negative behaviours could be under-reported and their importance to cardiometabolic risks therefore under-estimated. The 24-h dietary recall method may not fully reflect long-term habitual dietary behaviours. However, this concern is mitigated by the large sample size, thus increasing statistical power and the probability of revealing diverse dietary behaviours. The possibility of other confounders from unmeasured variables such as intake of other residual nutrients cannot be completely ruled out and requires strictly separate in-depth analyses in further research.

Despite these limitations, to the best of our knowledge, this is the first study to evaluate the sex-based differences in the association between insufficient riboflavin intake and cardiometabolic risks, including MetS, using current data obtained from a large representative Korean population. Few studies have evaluated the effect of riboflavin on cardiometabolic conditions according to menopausal status. Thus, more interventional studies are needed to

determine the mechanisms of sex-based differences related to riboflavin activities in humans.

In conclusion, we found a significant sex-specific association between insufficient intake of riboflavin and cardiometabolic risk in Korean adults. These findings underscore the importance of implementing sex-specific dietary education or counselling interventions, including sufficient riboflavin intake. The findings of this study may provide evidence to support improving public policies and assistance programmes that target at-risk groups, potentially reducing the burden of MetS and its cardiometabolic consequences.

#### AUTHOR DISCLOSURES

The authors declare that there are no conflicts of interest.

KNHANES was financially supported by the Health Promotion Fund with administrative support by the Ministry of Health and Welfare. The Health Promotion Fund and the Ministry of Health and Welfare had no role in the design, analysis or writing of this study.

#### REFERENCES

- Sowers JR. Update on the cardiometabolic syndrome. *Clin Cornerstone*. 2001;4:17-23. doi: 10.1016/S1098-3597(01)90026-2.
- Alberti K, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA et al. Harmonizing the metabolic syndrome a joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; American heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity. *Circulation*. 2009;120:1640-5. doi: 10.1161/CIRCULATIONAHA.109.192644.
- McNeill AM, Rosamond WD, Girman CJ, Golden SH, Schmidt MI, East HE et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. *Diabet Care*. 2005; 28:385-90. doi: 10.2337/diacare.28.2.385.
- Ervin RB. Prevalence of metabolic syndrome among adults 20 years of age and over, by sex, age, race and ethnicity, and body mass index: United States, 2003–2006. National Health Statistics Reports; no 13. Hyattsville, MD: National Center for Health Statistics; 2009.
- Korea Society of Cardiometabolic syndrome, Metabolic Syndrome Fact Sheet in Korea 2018. [cited 2018/10/06]; Available from: [http://kscms.org/en/uploads/Metabolic\\_Syndrome.pdf](http://kscms.org/en/uploads/Metabolic_Syndrome.pdf).
- Powers HJ. Riboflavin (vitamin B-2) and health. *Am J Clin Nutr*. 2003;77:1352-60. doi: 10.1093/ajcn/77.6.1352.
- Korea Health Statistics 2016: Korea National Health and Nutrition Examination Survey (KNHANES VII-1). Seoul: Korea Centers for Disease Control and Prevention; 2016.
- Kweon S, Kim Y, Jang MJ, Kim Y, Kim K, Choi S. Data resource profile: the Korea National Health and Nutrition Examination Survey (KNHANES). *Int J Epidemiol*. 2014;43: 69-77. doi: 10.1093/ije/dyt228.
- Nilsson PM, Nilsson JÅ, Berglund G. Population-attributable risk of coronary heart disease risk factors during long-term follow-up: the Malmö Preventive Project. *J Intern Med*. 2006;260:134-41. doi: 10.1111/j.1365-2796.2006.01671.x.
- U.S. Department of Health Human Services. Physical Activity Guidelines for Americans. Be active, healthy, and happy. ODPHP Publication No. U0036. Washington: U.S. Department of Health and Human Services; 2008.
- Grundey MS, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung and Blood Institute Scientific Statement. *Circulation*. 2005;112:2375-2. doi: 10.1161/CIRCULATIONAHA.105.169404.
- The Korean Nutrition Society. Dietary Reference Intakes for Koreans 2015, Seoul: The Korean Nutrition Society; 2015.
- Newman LJ, Lopez R, Cole HS, Boria MC, Cooperman JM. Riboflavin deficiency in women taking oral contraceptive agents. *Am J Clin Nutr*. 1978;31:247-9. doi: 10.1093/ajcn/31.2.247.
- Hsu CC, Wahlqvist ML, Wu IS, Chang YH, Chang IS, Tsai YF et al. Cardiometabolic disorder reduces survival prospects more than suboptimal body mass index irrespective of age or gender: a longitudinal study of 377,929 adults in Taiwan. *BMC Public Health*. 2018;18:142. doi: 10.1186/s12889-018-5038-0.
- Wahlqvist ML, Chang HY, Chen CC, Hsu CC, Chang WC, Wang WS et al. Is impaired energy regulation the core of the metabolic syndrome in various ethnic groups of the USA and Taiwan? *BMC Endocrine Disorders*. 2010;10:11. doi: 10.1186/1472-6823-10-11.
- Kiran T, Sudhir KT, Ashish KS, Surajit M, Sumit A. Riboflavin and health: A review of recent human research. *Crit Rev Food Sci Nutr*. 2017;57:3650-60. doi: 10.1080/10408398.2016.1145104.
- Samira E, Parvin M. Nutritional approaches for prevention and treatment of metabolic syndrome in adults. *J Paramed Sci*. 2013;4:123-34. doi: 10.22037/jps.v4i2.4206.
- Panagiotakos DB, Pitsavos C, Skoumas Y, Stefanadis C. The association between food patterns and the metabolic syndrome using principal components analysis: The ATTICA Study. *J Am Diet Assoc*. 2007;107:979-87. doi: 10.1016/j.jada.2007.03.006.
- Davi G, Santilli F, Patrono C. Nutraceuticals in diabetes and metabolic syndrome. *Cardiovasc Ther*. 2010;28:216-26. doi: 10.1111/j.1755-5922.2010.00179.x.
- Avignon A, Hokayem M, Bisbal C, Lambert K. Dietary antioxidants: do they have a role to play in the ongoing fight against abnormal glucose metabolism? *Nutrition*. 2012;28: 715-21. doi: 10.1016/j.nut.2012.01.001.
- Whayne TF Jr, Maulik N. Nutrition and the healthy heart with an exercise boost. *Can J Physiol Pharmacol*. 2012;90: 967-76. doi: 10.1139/y2012-074.
- Xu YJ, Tappia PS, Neki NS, Dhalla NS. Prevention of diabetes-induced cardiovascular complications upon treatment with antioxidants. *Heart Fail Rev*. 2014;19:113-21. doi: 10.1007/s10741-013-9379-6.
- Hultquist DE, Xu F, Quandt KS, Shlafer M, Mack CP. Evidence that NADPH-dependent methaemoglobin reductase and administered riboflavin protect tissue from oxidative injury. *Am J Hematol*. 1993;42:13-8.
- Mack C, Hultquist DE, Shlafer M. Myocardial flavin reductase and riboflavin: a potential role in decreasing reoxygenation injury. *Biochem Biophys Res Commun*. 1995; 212:35-40. doi: 10.1006/bbrc.1995.1932
- Tzoulaki I, Patel CJ, Okamura T, Chan Q, Brown IJ, Miura K et al. A nutrientwide association study on blood pressure. *Circulation*. 2012;126:2456-64. doi: 10.1161/CIRCULATIONAHA.112.114058.
- McNulty H, Doney RC, Strain JJ, Dunne A, Ward M, Molloy AM et al. Riboflavin lowers homocysteine in individuals homozygous for the MTHFR 677C->T polymorphism. *Circulation*. 2006;113:74-80. doi: 10.1161/CIRCULATIONAHA.105.580332.

27. Hustad S, Ueland PM, Vollset SE, Zhang Y, Bjorke-Monsen AL, Schneede J. Riboflavin as a determinant of plasma total homocysteine: effect modification by the methylenetetrahydrofolate reductase C677T polymorphism. *Clin Chem*. 2000;46:1065-71.
28. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. *JAMA*. 1995;274:1049-57.
29. Mazidi M, Pennathur S, Afshinnia F. Link of dietary patterns with metabolic syndrome: analysis of the National Health and Nutrition Examination Survey. *Nutrition & Diabetes*. 2017/3/20 [cited:2018/09/06]; Available from: <http://doi:10.1038/nutd.2017.11>.
30. Wang WS, Wahlqvist ML, Hsu CC, Chang HY, Chang WC, Chen CC. Age- and gender-specific population attributable risks of metabolic disorders on all-cause and cardiovascular mortality in Taiwan. *BMC Public Health*. 2012;12:111. doi: 10.1186/1471-2458-12-111.
31. Chang YH, Chen RC, Lee MS, Wahlqvist ML. Increased medical costs in elders with the metabolic syndrome are most evident with hospitalization of men. *Gend Med*. 2012;9:348-60. doi: 10.1016/j.genm.2012.08.005.
32. Cartier A, Côté M, Lemieux I, Pérusse L, Tremblay A, Bouchard C et al. Sex differences in inflammatory markers: what is the contribution of visceral adiposity? *Am J Clin Nutr*. 2009;89:1307-14. doi: 10.3945/ajcn.2008.27030.
33. Choi JY, Kim YN, Cho YO. Evaluation of riboflavin intakes and status of 20–64-year-old adults in South Korea. *Nutrients*. 2015;7:253-264. doi: 10.3390/nu7010253.
34. Zempleni J, Galloway JR, McCormick DB. Pharmacokinetics of orally and intravenously administered riboflavin in healthy humans. *Am J Clin Nutr*. 1996; 63:54-66. doi: 10.1093/ajcn/63.1.54.
35. Fukuwatari T, Shibata K. Urinary water-soluble vitamins and their metabolite contents as nutritional marker for evaluating vitamin intakes in young Japanese women. *J Nutr Sci Vitaminol*. 2008;54:223-9. doi:org/10.3177/jnsv.54.22.
36. European Food Safety Authority (EFSA). Dietary Reference Values for Riboflavin. *EFSA J*. 2017;18:4919. doi: 10.2903/j.efsa.2017.4919.

## Supplementary Tables

Supplementary Table 1. General characteristics of men and women, according to metabolic syndrome

Variables <sup>†</sup>	Men				Women			
	Metabolic syndrome		Total	<i>p</i> value <sup>‡</sup>	Metabolic syndrome		Total	<i>p</i> value
	Yes	No			Yes	No		
Total	654 (28.5)	1369 (71.5)	2023 (100.0)		1123 (23.5)	2916 (76.5)	4039 (100.0)	
Age (years)				<0.001				<0.001
19-29	18 (5.3)	208 (24.5)	226 (19.1)		10 (1.7)	383 (20.0)	393 (15.7)	
30-39	44 (11.9)	162 (16.8)	206 (15.4)		51 (6.0)	560 (19.4)	611 (16.2)	
40-49	83 (19.8)	206 (18.4)	289 (18.8)		116 (12.7)	644 (23.0)	760 (20.6)	
50-59	116 (23.9)	221 (17.8)	337 (19.5)		237 (25.1)	583 (19.7)	820 (21.0)	
60-69	189 (19.2)	282 (11.2)	471 (13.5)		326 (25.1)	428 (10.5)	754 (13.9)	
≥70	204 (19.8)	290 (11.3)	494 (13.7)		383 (29.4)	318 (7.5)	701 (12.7)	
Alcohol use				<0.001				0.004
Yes	99 (17.2)	138 (10.0)	237 (12.1)		21 (1.9)	109 (4.0)	130 (3.5)	
No	555 (82.8)	1231 (90.0)	1786 (87.9)		1102 (98.1)	2807 (96.0)	3909 (96.5)	
Regular physical activity				0.003				<0.001
Yes	298 (51.4)	744 (60.1)	1042 (57.6)		365 (35.4)	1396 (51.4)	1761 (47.7)	
No	356 (48.6)	625 (39.9)	981 (42.4)		758 (64.6)	1520 (48.6)	2278 (52.3)	
Oral contraceptive use								<0.001
Yes	0 (0.0)	0 (0.0)	0 (0.0)		281 (23.5)	483 (15.5)	764 (17.4)	
No	654 (100.0)	1369 (100.0)	2023 (100.0)		842 (76.5)	2433 (84.5)	3275 (82.6)	
Menopause								<0.001
Yes	0 (0.0)	0 (0.0)	0 (0.0)		919 (76.8)	1275 (36.0)	2194 (45.5)	
No	654 (100.0)	1369 (100.0)	2023 (100.0)		204 (23.2)	1641 (64.0)	1845 (54.5)	
Hypertension				<0.001				<0.001
Yes	450 (61.6)	356 (19.4)	806 (31.4)		744 (62.1)	492 (13.2)	1236 (24.7)	
No	204 (38.4)	1013 (80.6)	1217 (68.6)		379 (37.9)	2424 (86.8)	2803 (75.3)	
Diabetic mellitus				<0.001				<0.001
Yes	204 (25.3)	108 (5.0)	312 (10.8)		337 (28.8)	110 (3.1)	447 (9.1)	
No	450 (74.7)	1261 (95.0)	1711 (89.2)		786 (71.2)	2806 (96.9)	3592 (90.9)	
Dyslipidemia				<0.001				<0.001
Yes	368 (60.4)	325 (21.6)	693 (32.7)		640 (58.9)	659 (19.4)	1299 (28.7)	
No	286 (39.6)	1044 (78.4)	1330 (67.3)		483 (41.1)	2257 (80.6)	2740 (71.3)	
Central obesity				<0.001				<0.001
Yes	453 (71.7)	206 (15.4)	659 (31.4)		797 (70.9)	424 (13.0)	1221 (26.6)	
No	201 (28.3)	1163 (84.6)	1364 (68.6)		326 (29.1)	2492 (87.0)	2818 (73.4)	
Blood pressure (mmHg): systolic ≥130 or diastolic ≥85 or medication for hypertension				<0.001				<0.001
Yes	546 (80.5)	497 (29.7)	1043 (44.2)		886 (75.9)	651 (18.0)	1537 (31.6)	
No	108 (19.5)	872 (70.3)	980 (55.8)		237 (24.1)	2265 (82.0)	2502 (68.4)	

HDL: high-density lipoprotein; BMI: Body Mass Index; LDL: low-density lipoprotein; SFA: saturated fatty acids; MUFA: monounsaturated fatty acids; PUFA: polyunsaturated fatty acids

<sup>†</sup>Categorical variable: unweighted n (weighted %), continuous variable: mean±standard error.<sup>‡</sup>*p* values are from Rao-scott  $\chi^2$  test or ANOVA.

**Supplementary Table 1.** General characteristics of men and women, according to metabolic syndrome (cont.)

Variables <sup>†</sup>	Men				Women			
	Metabolic syndrome		Total	<i>p</i> value <sup>‡</sup>	Metabolic syndrome		Total	<i>p</i> value
	Yes	No			Yes	No		
Fasting blood glucose (mg/dL): ≥100 or medication for diabetes				<0.001				<0.001
Yes	512 (73.5)	390 (22.6)	902 (37.1)		790 (70.0)	442 (13.8)	1232 (27.0)	
No	142 (26.5)	979 (77.4)	1121 (62.9)		333 (30.0)	2474 (86.2)	2807 (73.0)	
Triglycerides (mg/dL) ≥150				<0.001				<0.001
Yes	450 (73.3)	236 (18.2)	686 (33.9)		646 (59.4)	262 (7.9)	908 (20.0)	
No	204 (26.7)	1133 (81.8)	1337 (66.1)		477 (40.6)	2654 (92.1)	3131 (80.0)	
HDL-cholesterol (mg/dL): men <40, women <50				<0.001				<0.001
Yes	348 (52.9)	168 (11.5)	516 (23.3)		890 (79.1)	767 (24.5)	1657 (37.3)	
No	306 (47.1)	1201 (88.5)	1507 (76.7)		233 (20.9)	2149 (75.5)	2382 (62.7)	
BMI (kg/m <sup>2</sup> )	27.1±0.18	23.6±0.09	24.6±0.10	<0.001	26.4±0.12	22.4±0.07	23.4±0.07	<0.001
Waist circumference (cm)	93.8±0.41	83.4±0.23	86.4±0.25	<0.001	88.4±0.32	76.2±0.21	79.1±0.23	<0.001
Systolic blood pressure (mmHg)	128±0.60	117±0.42	120±0.38	<0.001	128±0.60	112±0.31	115±0.33	<0.001
Diastolic blood pressure (mmHg)	81.5±0.47	76.2±0.29	77.7±0.26	<0.001	77.1±0.36	71.9±0.20	73.1±0.19	<0.001
Fasting blood glucose (mg/dL)	115±1.58	95.7±0.48	101±0.69	<0.001	113±1.04	92.3±0.31	97.1±0.41	<0.001
Total cholesterol (mg/dL)	194±1.96	188±1.17	190±1.05	0.008	197±1.44	192±0.78	193±0.69	0.002
Triglycerides (mg/dL)	232±9.75	114±2.20	148±3.55	<0.001	183±3.80	90.6±1.01	112±1.46	<0.001
LDL- cholesterol (mg/dL)	109±1.81	115±1.01	113±0.94	0.004	116±1.29	116±0.72	116±0.62	0.897
HDL- cholesterol (mg/dL)	41.3±0.42	50.6±0.33	47.9±0.28	<0.001	44.7±0.31	58.1±0.28	55.0±0.26	<0.001
Total energy intake (kcal/day)	2348±50.6	2419±34.1	2399±29.2	0.225	1596±23.8	1754±15.7	1717±13.6	<0.001
Carbohydrates intake (g/day)	354±7.45	349±4.23	350±3.73	0.579	273±4.41	273±2.53	273±2.30	0.986
Protein intake (g/day)	80.7±1.90	89.4±2.31	87.0±1.74	0.003	52.8±0.93	62.3±0.77	60.1±0.64	<0.001
Fat intake (g/day)	49.6±2.02	58.6±1.71	56.0±1.39	<0.001	29.6±0.82	41.6±0.66	38.8±0.57	<0.001
SFA intake (g/day)	14.2±0.70	16.9±0.52	16.1±0.42	0.002	8.24±0.26	11.9±0.20	11.0±0.17	<0.001
MUFA intake (g/day)	15.8±0.79	19.0±0.61	18.1±0.50	0.001	9.21±0.31	13.2±0.23	12.2±0.20	<0.001
PUFA intake (g/day)	12.4±0.46	14.6±0.50	13.9±0.40	<0.001	7.60±0.22	10.4±0.20	9.74±0.17	<0.001
Dietary fiber intake (g/day)	27.6±0.69	26.5±0.46	26.8±0.40	0.147	22.1±0.44	21.9±0.31	22.0±0.26	0.752
Total riboflavin intake (mg/day)	1.53±0.05	1.65±0.04	1.61±0.03	0.038	1.05±0.02	1.25±0.02	1.21±0.01	<0.001
Sources of riboflavin intake (mg/day)								
Cereals and grains	0.25±0.02	0.27±0.01	0.27±0.01	0.977	0.17±0.01	0.19±0.00	0.18±0.00	<0.001
Meats	0.19±0.01	0.25±0.01	0.23±0.01	<0.001	0.10±0.01	0.16±0.01	0.15±0.00	<0.001
Vegetables	0.26±0.01	0.24±0.01	0.24±0.01	0.089	0.21±0.01	0.18±0.00	0.19±0.00	0.002
Eggs	0.21±0.02	0.21±0.01	0.21±0.01	0.221	0.15±0.01	0.21±0.01	0.20±0.01	<0.001
Fruits	0.06±0.00	0.06±0.00	0.06±0.00	0.773	0.06±0.00	0.06±0.00	0.06±0.00	0.154
Dairy products	0.10±0.01	0.12±0.01	0.11±0.01	0.209	0.08±0.01	0.11±0.00	0.10±0.00	<0.001
Supplements	0.46±0.05	0.49±0.04	0.48±0.02	0.529	0.27±0.00	0.33±0.00	0.32±0.00	<0.001

HDL: high-density lipoprotein; BMI: Body Mass Index; LDL: low-density lipoprotein; SFA: saturated fatty acids; MUFA: monounsaturated fatty acids; PUFA: polyunsaturated fatty acids

<sup>†</sup>Categorical variable: unweighted n (weighted %), continuous variable: mean±standard error.

<sup>‡</sup>*p* values are from Rao-scott  $\chi^2$  test or ANOVA.

**Supplementary Table 2.** General characteristics of pre- and post-menopausal women, according to metabolic syndrome

Variables <sup>†</sup>	Pre-menopausal women				Post-menopausal women			
	Metabolic syndrome		Total	<i>p</i> value <sup>‡</sup>	Metabolic syndrome		Total	<i>p</i> value
	Yes	No			Yes	No		
Total	204 (10.0)	1641 (90.0)	1845 (100)		919 (39.6)	1275 (60.4)	2194 (100)	
Age (years)				<0.001				<0.001
19-29	10 (7.1)	383 (31.2)	393 (28.8)		0 (0.0)	0 (0.0)	0 (0.0)	
30-39	51 (26.0)	558 (30.2)	609 (29.7)		0 (0.0)	2 (0.1)	2 (0.1)	
40-49	104 (48.0)	597 (33.1)	701 (34.6)		12 (2.0)	47 (5.0)	59 (3.8)	
50-59	38 (18.8)	101 (5.5)	139 (6.8)		199 (27.0)	482 (45.0)	681 (37.9)	
60-69	1 (0.0)	0 (0.0)	1 (0.0)		325 (32.7)	428 (29.2)	753 (30.6)	
≥70	0 (0.0)	2 (0.1)	2 (0.1)		383 (38.3)	316 (20.8)	699 (27.7)	
Alcohol use				0.171				0.621
Yes	7 (3.0)	90 (5.5)	97 (5.3)		14 (1.6)	19 (1.3)	33 (1.4)	
No	197 (97.0)	1551 (94.5)	1748 (94.7)		905 (98.4)	1256 (98.7)	2161 (98.6)	
Regular physical activity				0.073				<0.001
Yes	92 (45.7)	833 (53.2)	925 (52.5)		273 (32.3)	563 (48.3)	836 (41.9)	
No	112 (54.3)	808 (46.8)	920 (47.5)		646 (67.7)	712 (51.7)	1358 (58.1)	
Oral contraceptive use				0.389				0.002
Yes	33 (15.6)	215 (13.2)	248 (13.4)		248 (25.8)	268 (19.6)	516 (22.0)	
No	171 (84.4)	1426 (86.8)	1597 (86.6)		671 (74.2)	1007 (80.4)	1678 (78.0)	
Hypertension				<0.001				<0.001
Yes	66 (30.1)	76 (4.1)	142 (6.7)		678 (71.7)	416 (29.3)	1094 (46.1)	
No	138 (69.9)	1565 (95.9)	1703 (93.3)		241 (28.3)	859 (70.7)	1100 (53.9)	
Diabetic mellitus				<0.001				<0.001
Yes	40 (17.7)	13 (0.7)	53 (2.4)		297 (32.1)	97 (7.2)	394 (17.1)	
No	164 (82.3)	1628 (99.3)	1792 (97.6)		622 (67.9)	1178 (92.8)	1800 (82.9)	
Dyslipidemia				<0.001				<0.001
Yes	98 (52.9)	144 (7.6)	242 (12.1)		542 (60.6)	515 (40.5)	1057 (48.5)	
No	106 (47.1)	1497 (92.4)	1603 (87.9)		377 (39.4)	760 (59.5)	1137 (51.5)	
Central obesity				<0.001				<0.001
Yes	156 (75.8)	173 (10.1)	329 (16.7)		641 (69.4)	251 (18.2)	892 (38.5)	
No	48 (24.2)	1468 (89.9)	1516 (83.3)		278 (30.6)	1024 (81.8)	1302 (61.5)	
Blood pressure (mmHg): systolic ≥130 or diastolic ≥85 or medication for hypertension				<0.001				<0.001
Yes	106 (50.2)	144 (8.0)	250 (12.2)		780 (83.7)	507 (35.9)	1287 (54.8)	
No	98 (49.8)	1497 (92.0)	1595 (87.8)		139 (16.3)	768 (64.1)	907 (45.2)	
Fasting blood glucose (mg/dL): ≥100 or medication for diabetes				<0.001				<0.001
Yes	143 (68.9)	147 (8.5)	290 (14.5)		647 (70.3)	295 (23.2)	942 (41.9)	
No	61 (31.1)	1494 (91.5)	1555 (85.5)		272 (29.7)	980 (76.8)	1252 (58.1)	

HDL: high-density lipoprotein; BMI: Body Mass Index; LDL: low-density lipoprotein; SFA: saturated fatty acids; MUFA: monounsaturated fatty acids; PUFA: polyunsaturated fatty acids

<sup>†</sup>Categorical variable: unweighted n (weighted %), continuous variable: mean±standard error.<sup>‡</sup>*p* values are from Rao-scott  $\chi^2$  test or ANOVA.

**Supplementary Table 2.** General characteristics of pre- and post-menopausal women, according to metabolic syndrome (cont.)

Variables <sup>†</sup>	Pre-menopausal women				Post-menopausal women			
	Metabolic syndrome		Total	<i>p</i> value <sup>‡</sup>	Metabolic syndrome		Total	<i>p</i> value
	Yes	No			Yes	No		
Triglycerides (mg/dL) ≥150				<0.001				<0.001
Yes	128 (69.0)	115 (6.4)	243 (12.7)		518 (56.5)	147 (10.5)	665 (28.7)	
No	76 (31.0)	1526 (93.6)	1602 (87.3)		401 (43.5)	1128 (89.5)	1529 (71.3)	
HDL-cholesterol (mg/dL) <50				<0.001				<0.001
Yes	175 (83.9)	414 (23.7)	589 (29.7)		715 (77.6)	353 (25.9)	1068 (46.4)	
No	29 (16.1)	1227 (76.3)	1256 (70.3)		204 (22.4)	922 (74.1)	1126 (53.6)	
BMI (kg/m <sup>2</sup> )	27.5±0.32	22.1±0.08	22.6±0.10	<0.001	26.0±0.12	23.1±0.10	24.3±0.09	<0.001
Waist circumference (cm)	89.5±0.70	74.6±0.25	76.1±0.28	<0.001	88.1±0.35	79.1±0.27	82.6±0.28	<0.001
Systolic blood pressure (mmHg)	120±1.21	107±0.31	108±0.32	<0.001	130±0.64	120±0.58	124±0.44	<0.001
Diastolic blood pressure (mmHg)	80.0±0.83	70.8±0.25	71.7±0.26	<0.001	76.2±0.36	73.9±0.32	74.9±0.24	<0.001
Fasting Blood glucose (mg/dL)	111±1.98	90.1±0.33	92.1±0.40	<0.001	114±1.24	96.3±0.55	103±0.64	<0.001
Total cholesterol (mg/dL)	203±3.16	185±0.91	187±0.91	<0.001	195±1.53	203±1.28	200±0.98	<0.001
Triglycerides (mg/dL)	205±9.31	84.2±1.20	96.3±1.68	<0.001	177±3.70	102±1.56	132±2.02	<0.001
LDL-cholesterol (mg/dL)	118±2.66	110±0.79	111±0.78	0.003	115±1.41	125±1.21	121±0.91	<0.001
HDL-cholesterol (mg/dL)	43.9±0.69	58.5±0.37	57.0±0.36	<0.001	44.9±0.35	57.5±0.42	52.5±0.34	<0.001
Total energy intake (kcal/day)	1792±56.2	1809±19.6	1807±18.44	0.781	1536±22.6	1657±22.3	1610±16.0	<0.001
Carbohydrates intake (g/day)	282±9.79	268±3.03	270±2.93	0.177	270.4±4.35	282.1±3.61	278±2.83	0.036
Protein intake (g/day)	61.7±2.17	65.6±0.96	65.2±0.88	0.108	50.1±0.99	56.5±1.05	54.0±0.75	<0.001
Fat intake (g/day)	42.3±1.97	47.1±0.85	46.6±0.81	0.023	25.7±0.76	31.9±0.96	29.5±0.66	<0.001
SFA intake (g/day)	12.3±0.70	13.8±0.28	13.6±0.26	0.044	7.02±0.21	8.47±0.25	7.89±0.17	<0.001
MUFA intake (g/day)	14.0±0.79	15.2±0.30	15.1±0.28	0.142	7.78±0.28	9.60±0.32	8.88±0.23	<0.001
PUFA intake (g/day)	10.1±0.50	11.3±0.26	11.2±0.24	0.035	6.84±0.23	8.86±0.32	8.06±0.21	<0.001
Dietary fiber intake (g/day)	21.7±0.99	20.4±0.35	20.5±0.33	0.225	22.2±0.49	24.6±0.46	23.7±0.34	<0.001
Total riboflavin intake (mg/day)	1.19±0.04	1.31±0.02	1.30±0.02	0.007	1.00±0.03	1.16±0.03	1.10±0.02	<0.001
Sources of riboflavin intake (mg/day)								
Cereals and grains	0.20±0.04	0.21±0.01	0.21±0.01	0.084	0.17±0.02	0.17±0.00	0.16±0.00	0.574
Meats	0.16±0.02	0.19±0.01	0.19±0.01	0.097	0.08±0.01	0.10±0.01	0.09±0.00	0.082
Vegetables	0.19±0.01	0.17±0.00	0.17±0.00	0.016	0.22±0.01	0.20±0.01	0.21±0.01	0.372
Eggs	0.22±0.03	0.23±0.01	0.23±0.01	0.674	0.13±0.01	0.18±0.01	0.16±0.01	<0.001
Fruits	0.06±0.01	0.06±0.00	0.06±0.00	0.845	0.06±0.00	0.08±0.00	0.07±0.00	<0.001
Dairy products	0.08±0.01	0.12±0.01	0.11±0.01	0.018	0.07±0.01	0.09±0.01	0.08±0.00	0.049
Supplements	0.29±0.03	0.34±0.00	0.34±0.00	0.059	0.27±0.01	0.33±0.03	0.30±0.00	0.054

HDL: high-density lipoprotein; BMI: Body Mass Index; LDL: low-density lipoprotein; SFA: saturated fatty acids; MUFA: monounsaturated fatty acids; PUFA: polyunsaturated fatty acids

<sup>†</sup>Categorical variable: unweighted n (weighted %), continuous variable: mean±standard error.

<sup>‡</sup>*p* values are from Rao-scott  $\chi^2$  test or ANOVA.